Drug intelligence / Profile preview

MP0714

Development stage
Preclinical
Lead developer
Molecular Partners
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

MP0714 is a preclinical-stage targeted alpha radiopharmaceutical being developed by Molecular Partners. It consists of a designed ankyrin repeat protein (DARPin) vector targeting delta-like ligand 3 (DLL3) conjugated to either the alpha-emitting radioisotope actinium-225 (225Ac) for therapy or the beta-emitting radioisotope lutetium-177 (177Lu) for imaging, forming a theranostic pair. MP0714 is designed to treat small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs) by selectively delivering cytotoxic radiation to DLL3-expressing tumor cells. An early-access clinical program for compassionate care has been initiated in South Africa by the Nuclear Medicine Research Institute (NuMeRI) to image and treat patients using this theranostic pair.

Other names
177Lu/225Ac DLL3 Radio-DARPin225Ac-DLL3 Radio-DARPinDLL3-targeting Radio-DARPin (177Lu/225Ac)
02

Targets

Beyond the preview

Go deeper on MP0714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP0714.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call